<DOC>
	<DOCNO>NCT02370537</DOCNO>
	<brief_summary>This study 2-part open-label , randomize , crossover , multicenter , non-therapeutic Phase II study investigate presence pancreatic exocrine insufficiency ( PEI ) patient Type 2 diabetes mellitus ( T2DM ) , investigate pharmacokinetics ( PK ) EPANOVA® ( omega-3 carboxylic acid ) omega-3-acid ethyl ester ( OMACOR® , Abbott Healthcare Products Ltd ) follow single oral dose patient different degree PEI .</brief_summary>
	<brief_title>A Study Investigate How Common Pancreatic Exocrine Insufficiency ( PEI ) Patients With Type 2 Diabetes Also Investigate Uptake Single Dose EPANOVA® OMACOR® Patients With Different Degrees PEI</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Male female age ≥18 year ≤70 year , suitable vein cannulation repeat venipuncture . Clinically diagnose Type 2 diabetic ( American Diabetes Association guideline ; ) , oral antibiotic drug use ≥3 month HbA1c value ≥6.5 % ≤9.0 % Visit 1 . Have body mass index ≥18 kg/m2 ≤40 kg/m2 weigh least 50 kg . Intolerance Omega3 fatty acid , ethyl ester fish . On insulin therapy treat injectable Glucagonlike peptide1 ( GLP1 ) . Treated bile acid sequestrants . Serum level TGs &gt; 10 mmol/L time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>omega-3 carboxylic acid</keyword>
</DOC>